Form D · Pharmaceuticals

DARA BioSciences, Inc.

Raleigh, NC · CIK 0000919745

Offering snapshot reported Jan 31, 2012 · SEC filing

Reported sold: $1.45M
Investors reported: 10
Minimum accepted: $0
First sale: Jan 17, 2012

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jan 31, 2012	Initial	$1,448,928	No comparison	10	SEC filing
Mar 9, 2010	Initial	$1,716,500	No comparison	22	SEC filing
Jun 22, 2009	Initial	$1,397,000	No comparison	26	SEC filing

Offering details

Securities: Equity
Exemptions: 06
Duration over one year: No
Business combination: Yes

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-172698

DARA issued 1,114,560 shares to Oncogenerix stockholders in connection with the merger. The closing price of DARA stock on 1/13/12 was $1.30. If DARA achieves certain milestones within 60 months, Onco stockholders will receive up to 1,114,560 add'l shares

Source: Form D, filed Jan 31, 2012. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Christopher Clement	Director, Executive
Haywood D Cochrane	Director
David Drutz	Director, Executive
Richard A Franco	Director, Executive
Steve Gorlin	Director
Gail F Liebarman	Director
Gail F Lieberman	Director
Ann A Rosar	Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

8601 Six Forks Road Suite 160
Raleigh, NC, 27615